16S gut community of the Cameron County Hispanic CohortOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers profiled the 16S rRNA gut microbiome of 63 Mexican American adults from the Cameron County Hispanic Cohort (CCHC), a border-region population with high rates of obesity and type 2 diabetes (T2D). They compared these profiles to 213 Human Microbiome Project (HMP) stool samples representing a healthy reference population.
How was it studied?
Stool samples underwent 16S rRNA gene sequencing of the V1-V3 region on Roche 454 pyrosequencing, processed through QIIME with OTUs picked against the Silva database. The team also ran SparCC network correlation analysis across the CCHC plus three additional cohorts, including a Mexican type 1 diabetes cohort and an Irish elderly cohort.
What did they find?
CCHC subjects had significantly higher Firmicutes and Actinobacteria and lower Bacteroidetes than HMP subjects, with elevated Erysipelotrichaceae, Ruminococcaceae, and a higher Firmicutes to Bacteroidetes ratio. No taxon was significantly associated with BMI, age, diabetes status, or other clinical measures after correction, and CCHC subjects showed about threefold lower inter-subject variance than HMP. A network of seven genera, mostly butyrate producers in Ruminococcaceae, was consistently interconnected across all four datasets and was largely elevated in the CCHC.
Why it matters
The authors suggest this disease-associated gut community structure likely establishes early in life and persists, potentially compounding genetic and lifestyle risk for obesity, T2D, and non-alcoholic fatty liver disease in this population. The same butyrate-producer enrichment may also help explain the CCHC's comparatively low colorectal cancer rates.